BioXcel Therapeutics (BTAI) Market Capitalization (2018 - 2026)

BioXcel Therapeutics has reported Market Capitalization for 9 years, with the latest figure at $44.1 million in Q2 2026.

• On a quarterly basis, Market Capitalization rose 268.38% year-over-year to $44.1 million in Q2 2026; TTM through Jun 2026 was $44.1 million, a 268.38% increase from a year earlier, with the FY2025 full-year figure at $19.5 million, up 28.85% from the prior year.
• Market Capitalization was $44.1 million for Q2 2026 at BioXcel Therapeutics, up from $36.3 million in the prior quarter.
• The five-year high for Market Capitalization was $604.6 million in Q4 2022, with the low at $11.1 million in Q1 2025.
• Average Market Capitalization over 5 years is $174.3 million, with a median of $62.9 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Market Capitalization plunged 88.3% in 2025, then surged 268.38% in 2026.
• Over 5 years, Market Capitalization stood at $604.6 million in 2022, then tumbled by 85.4% to $88.3 million in 2023, then plunged by 82.83% to $15.2 million in 2024, then rose by 28.85% to $19.5 million in 2025, then soared by 125.98% to $44.1 million in 2026.
• The last three Market Capitalization figures came in at $44.1 million (Q2 2026), $36.3 million (Q1 2026), and $19.5 million (Q4 2025), per Business Quant data.